



3rd January 2017

Information to Patient Organisations for people with diabetes: end of temporary supply shortage of certain presentations of INSUMAN® BASAL and INSUMAN® COMB 25 (insulin human)

Dear Colleagues

In November 2015 Sanofi wrote to you to highlight a lack of availability of certain presentations of Insuman® Basal and Insuman® Comb 25 (the active substance for both is insulin human). This was due to limited manufacturing capacity at the Sanofi manufacturing site.

Sanofi would now like to inform you of the resolution of these shortages in the United Kingdom.

The presentations concerned are:

- Insuman® Basal 100 IU/mL suspension for injection in a cartridge (3ml x 5 cartridges)
- Insuman® Comb 25 100 IU/mL suspension for injection in a cartridge (3ml x 5 cartridges)
- Insuman® Basal Solostar® 100 IU/mL suspension for injection in a pre-filled pen (3ml x 5 pre-filled pens)
- Insuman® Comb 25 Solostar® 100 IU/mL suspension for injection in a pre-filled pen (3ml x 5 pre-filled pens)

Normal production resumed in September 2016. Stocks in the different distribution centres, hospitals and pharmacies are currently being replenished and stocks will be back to normal **by the end of March 2017**.

Implications for patients

The re-conversion of patients initially treated with Insuman®, who were switched to an alternative insulin and who would like to come back to Insuman®, should be performed under the supervision of a Healthcare Professional and with close monitoring of blood glucose levels. Patients may need to be trained again in the use of the Insuman delivery device that is specific to each device manufacturer.



Reporting of side effects

Patients and their carers can report a suspected side effect in the following ways:

- On the Yellow Card website: www.yellowcard.mhra.gov.uk.
- On a Yellow Card form, which you can find at pharmacies, GP surgeries or from the Yellow Card hotline by calling freephone 0808 100 3352 during business hours. The Yellow Card form can also be downloaded, to print and complete (the form should be returned to the address on the bottom of the form no stamp is needed). Download a Patient Yellow Card form to print and complete at www.yellowcard.mhra.gov.uk.
- To the Yellow Card hotline on freephone 0808 100 3352 during business hours.

Reports can also be made to the **Sanofi UK Pharmacovigilance** department at: Sanofi, One Onslow Street, Guildford, Surrey, GU1 4YS, UK. Tel: 01483 554242, Fax: 01483 554806, Email: uk-drugsafety@sanofi.com.

Further information

Should you have additional questions relating to the shortage, please call the **Freephone 24-hour Sanofi Diabetes Care Line on 08000 35 25 25**.

Yours faithfully,

Victoria HAYES

Public Affairs & Advocacy Lead

UK & Ireland

Tel.: +44 (0) 1483 50 44 68

Mob. +44 (0) 7921 054913

One Onslow Street, Guildford, Surrey, GU1 4YS, UK